The most significant incretin which is deficient in type 2 diabetics.
The incretin effect refers to the physiologic phenomenon by which oral glucose administration stimulates more insulin, secretion, than intravenous glucose administration.
GLP-1 slows gastric emptying, suppresses glucagon secretion, mediates appetite reduction by activating GLP-1 receptors in the pancreas, brain and vagal efferent nerve.
Suppresses glucagon production, physiologically releases insulin and in animal studies increased beta cell mass from pancreatic duct stem cells.
Increases within minutes.
Incretins such as GLP-1 are secreted by endocrine cells in the small intestine in response to the ingestion of food, mainly glucose and fat and act upon receptors stimulating pancreatic insulin secretion.
GLP-1 (glucagon-like peptide-1) is made primarily by specialized enteroendocrine L cells in the intestinal epithelium—most abundantly in the distal small bowel (ileum) and colon.
They release it after nutrient exposure, particularly after a meal.
Other production site A separate, smaller GLP-1-producing system exists in the CNS: preproglucagon-expressing neurons concentrated in the nucleus tractus solitarius (NTS) of the caudal brainstem.
This neural GLP-1 participates mainly in central autonomic and appetite-related signaling.
The pancreas is principally a target, not the main source, of circulating GLP-1.
In pancreatic β cells, GLP-1 receptor signaling enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion indirectly, slows gastric emptying, and contributes to satiety signaling.
Mechanistically, tissue-specific processing of proglucagon matters: intestinal L cells and NTS neurons express prohormone convertase 1/3, which permits generation of active GLP-1; pancreatic α cells preferentially process proglucagon toward glucagon instead.
GLP-1 has a short half-life due to the rapid breakdown by dipeptyl-4 (DPP-5).
Glucagon-like peptide-1 (GLP-1) is an incretin released by the duodenum that inhibits relaxation of the stomach.
Its inhibition causes increased stretch of the stomach, increasing activation of proximal gastric stretch receptors, and slows overall gut motility, increasing the duration of satiety.
This effect is used to increase weight loss and treat obesity through GLP-1 agonists.
Increase release following gastric bypass when large volumes of chyme presented to the hindgut and results in improvement in diabetes.
Most made in enteroendocrine L cells in the distal ileum and colon and plasma levels increase within minutes of eating.
Also produced by discrete subset of neurons within the brain stem.
Has a short half-life when released from the gastrointestinal tract so it is given as an injection where it is bound to albumin and slowly released.
A combination of endocrine and neural signals promote secretion before digested food transits via the gut to directly stimulate L cells in the small bowel and colon.
Proximately located L cells in duodenum and jejunum exist but their contributions of such cells in the rapid increase in plasma GLP-1 is not clear.
Plasma levels low in fasting state in the range of 5-10 pmol/L and reach 15-50 pmol/L after eating.
Circulating levels decrease rapidly because of enzymatic inactivation mainly by dipeptyl peptidase-4 (DDP-4) and renal clearance.
GLP-1 based therapies for DM include mimetic exenatide, and a dipeptidyl peptidase 4 inhibitor, sitagliptin phosphate.
A product of pro glucagon processing in the gut and CNS.
Secreted by L-cells of the intestine postprandially.
A gut-derived peptide with glucose and immune modulatory function.
It is secreted in response to nutritional and inflammatory stimuli from intestinal L-Cells and pancreatic alpha cells.
Regulates blood glucose levels via the stimulation of glucose-dependent insulin secretion from pancreatic beta cells and inhibition of glucagon release from pancreatic alpha cells.
Has 36-37 amino acids.
Synthesized in brainstem and projects to the brain including PVN.
Incretins.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates release following oral intake of glucose.
The effects of incretin hormones are diminished in patients with type II diabetes.
GLP-1 function is retained in type II diabetes and administration of GLP-one receptor agonists can restore the incretin effect in these patients.
Incretin effect is reduced in patients with type 2 diabetes.
Postprandial GLP-1 levels are decreased in patients with type two diabetes.
GLP-1 inhibits food intake.
Half life is short due to rapid inactivation via dipeptidyl peptidase 4.
GLP-1 indirectly effects fullness and satiety by delaying gastric emptying and distention of the stomach and directly effects receptors in CNS to regulate appetite
Stimulates insulin production when glucose levels are elevated.
Blunts glucagon when glucose levels are elevated, preserving appropriate glucagon responses to hypoglycemia.
Modulates gastric emptying with decreased entry of caloric content into small intestine per unit time.
GLP-1 analogs such as exenatide and liraglutide have long half-lives unlike GLP-1 which is broken down in 2 minutes.
GLP_1 analogs require subcutaneous injection.
GLP_1 analogs are associated with a 1% reduction in HgbA1C and are associated with weight loss.
GLP_1 analogues are associated with nausea in 10-15% of cases.
GLP-1 analogues are associated with pancreatitis.